
Kidney Cancer
Latest News
Latest Videos

CME Content
More News
This clearance adds onto a previous indication for the BioTraceIO platform in liver tumor ablation.

The combination also yielded durable responses in a subset of patients with sporadic papillary renal cell carcinoma.

Singer reflects on how clinical trial design, patient selection, and biomarker research are driving more individualized therapy choices.

Take a look through key stories from last month, including regulatory news, trial updates, and other practice-changing advancements.

Five-year data from the phase 3 KEYNOTE-426 trial confirm the clinical benefits of front-line pembrolizumab plus axitinib in advanced ccRCC.

MRWS was shown to prolong the time off systemic therapy and was associated with favorable tolerability.

A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.

Data from the #HOPE4KIDNEY trial is intended to support submission for regulatory clearance of the Edison Histotripsy System.

The new drug application is backed by data from the phase 2/3 FRUSICA-2 trial.
ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.

The approvals are supported by findings from the phase 3 CheckMate-67T trial.

"Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology.
















